Goldman Sachs Group Inc Larimar Therapeutics, Inc. Transaction History

Goldman Sachs Group Inc

  • $706 Billion
  • Q2 2025

A detailed history of Goldman Sachs Group Inc transactions in Larimar Therapeutics, Inc. stock. As of the latest transaction made, Goldman Sachs Group Inc holds 131,622 shares of LRMR stock, worth $560,709. This represents 0.0% of its overall portfolio holdings.

Number of Shares
131,622
Previous 2,671,271 95.07%
Holding current value
$560,709
Previous $5.74 Million 93.38%
% of portfolio
0.0%
Previous 0.0%

Shares

19 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2025

Aug 14, 2025
SELL
$1.71 - $3.25 $4.34 Million - $8.25 Million
-2,539,649 Reduced 95.07%
131,622 $380,000
Q1 2025

May 09, 2025
SELL
$2.15 - $4.18 $3.18 Million - $6.19 Million
-1,480,957 Reduced 35.67%
2,671,271 $5.74 Million
Q4 2024

Feb 11, 2025
SELL
$3.8 - $9.29 $369,599 - $903,573
-97,263 Reduced 2.29%
4,152,228 $15.9 Million
Q3 2024

Nov 14, 2024
SELL
$6.3 - $10.68 $524,802 - $889,665
-83,302 Reduced 1.92%
4,249,491 $27.8 Million
Q2 2024

Aug 13, 2024
BUY
$6.33 - $9.89 $5.79 Million - $9.05 Million
915,195 Added 26.78%
4,332,793 $31.4 Million
Q1 2024

May 15, 2024
BUY
$4.2 - $13.28 $13.8 Million - $43.6 Million
3,283,731 Added 2452.98%
3,417,598 $25.9 Million
Q4 2023

Feb 13, 2024
SELL
$2.35 - $4.71 $4,074 - $8,167
-1,734 Reduced 1.28%
133,867 $609,000
Q3 2023

May 14, 2024
BUY
$3.08 - $4.49 $5,340 - $7,785
1,734 Added 1.3%
135,601 $535,000
Q3 2023

Nov 14, 2023
BUY
$3.08 - $4.49 $1,552 - $2,262
504 Added 0.37%
135,601 $535,000
Q2 2023

May 14, 2024
SELL
$3.13 - $5.27 $130,783 - $220,201
-41,784 Reduced 23.62%
135,097 $422,000
Q2 2023

Aug 14, 2023
SELL
$3.13 - $5.27 $130,783 - $220,201
-41,784 Reduced 23.62%
135,097 $422,000
Q1 2023

May 14, 2024
BUY
$4.0 - $6.68 $256,780 - $428,822
64,195 Added 56.97%
176,881 $801,000
Q1 2023

May 11, 2023
BUY
$4.0 - $6.68 $256,780 - $428,822
64,195 Added 56.97%
176,881 $801,000
Q4 2022

May 14, 2024
BUY
$2.73 - $5.08 $141,293 - $262,920
51,756 Added 84.94%
112,686 $465,000
Q4 2022

Feb 13, 2023
BUY
$2.73 - $5.08 $141,293 - $262,920
51,756 Added 84.94%
112,686 $465,000
Q3 2022

May 14, 2024
SELL
$1.53 - $3.64 $111,593 - $265,490
-72,937 Reduced 54.48%
60,930 $195,000
Q3 2022

Nov 10, 2022
BUY
$1.53 - $3.64 $93,222 - $221,785
60,930 New
60,930 $0
Q4 2021

Feb 14, 2022
SELL
$8.86 - $13.47 $115,649 - $175,823
-13,053 Closed
0 $0
Q3 2021

Nov 10, 2021
BUY
$9.61 - $15.11 $125,439 - $197,230
13,053 New
13,053 $151,000

Others Institutions Holding LRMR

# of Institutions
126
Shares Held
65.9M
Call Options Held
4.83M
Put Options Held
83.7K
View Full List

About Larimar Therapeutics, Inc.

LRMR Quotes by TradingView
  • Ticker LRMR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 43,269,200
  • Market Cap $184M
  • Description
  • Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 1 clinical trial for the treatment of Friedreich's ataxia, a rare, progressive, and fatal genetic disease. T...
More about LRMR
Track This Portfolio

Track Goldman Sachs Group Inc Portfolio

Follow Goldman Sachs Group Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Goldman Sachs Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Goldman Sachs Group Inc with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email